A more detailed analysis of the prognostic impact of TP53 mutations on OS and PFS revealed no significant differences in the OS of all MDS patients, regardless of mutation status; the median OS was 138 months in the TP53 wild-type group and 80.9 months in the TP53-mutant group (p = 0.09) (Figure 3A). Here, TP53 is linked to myelodysplastic syndrome.